

# Elena Bresin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9191258/publications.pdf>

Version: 2024-02-01

58  
papers

5,229  
citations

147566  
31  
h-index

168136  
53  
g-index

58  
all docs

58  
docs citations

58  
times ranked

3416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1844-1859.	2.2	818
2	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. <i>Blood</i> , 2006, 108, 1267-1279.	0.6	652
3	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 475-486.	3.0	308
4	Familial haemolytic uraemic syndrome and an MCP mutation. <i>Lancet, The</i> , 2003, 362, 1542-1547.	6.3	303
5	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. <i>Human Molecular Genetics</i> , 2003, 12, 3385-3395.	1.4	291
6	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. <i>Blood</i> , 2014, 124, 1715-1726.	0.6	288
7	Outcome of Renal Transplantation in Patients with Non-“Shiga Toxin”-Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 88-99.	2.2	201
8	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Blood</i> , 2002, 100, 778-785.	0.6	200
9	Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 940-949.	3.0	154
10	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1237-1247.	2.2	146
11	Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1177-1183.	3.0	129
12	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. <i>Molecular Immunology</i> , 2016, 71, 131-142.	1.0	126
13	Mutations in <i>FN1</i> cause glomerulopathy with fibronectin deposits. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2538-2543.	3.3	125
14	Autosomal-dominant Alport syndrome: Natural history of a disease due to COL4A3 or COL4A4 gene. <i>Kidney International</i> , 2004, 65, 1598-1603.	2.6	124
15	Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. <i>Clinical Genetics</i> , 2014, 86, 252-257.	1.0	121
16	A Novel Atypical Hemolytic Uremic Syndrome-Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor H-Dependent Complement Regulation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 209-219.	3.0	89
17	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 283-294.	3.0	89
18	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. <i>Thrombosis and Haemostasis</i> , 2009, 101, 233-238.	1.8	85

#	ARTICLE	IF	CITATIONS
19	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006, 96, 454-464.	1.8	72
20	An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. <i>American Journal of Kidney Diseases</i> , 2019, 74, 56-72.	2.1	71
21	Successful Split Liver-Kidney Transplant for Factor H Associated Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 201-206.	2.2	60
22	A novel nonsense mutation in the PKD1 gene (C3817T) is associated with autosomal dominant polycystic kidney disease (ADPKD) in a large three-generation Italian family. <i>Human Molecular Genetics</i> , 1995, 4, 1331-1335.	1.4	59
23	Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2246-2259.	0.4	59
24	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. <i>Blood</i> , 2005, 106, 925-928.	0.6	57
25	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. <i>Journal of Immunology</i> , 2017, 199, 1021-1040.	0.4	56
26	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. <i>American Journal of Transplantation</i> , 2013, 13, 2201-2206.	2.6	51
27	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1011-1019.	2.2	47
28	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 224-238.	2.1	45
29	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. <i>Molecular Immunology</i> , 2007, 44, 1704-1708.	1.0	41
30	Autosomal dominant polycystic kidney disease (ADPKD) in an Italian family carrying a novel nonsense mutation and two missense changes in exons 44 and 45 of the PKD1 gene. , 1996, 65, 155-159.		40
31	Autosomal recessive Alport syndrome: an in-depth clinical and molecular analysis of five families. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 665-671.	0.4	40
32	Detection of mutations in human genes by a new rapid method: cleavage fragment length polymorphism analysis (CFLPA). <i>Molecular and Cellular Probes</i> , 1997, 11, 155-160.	0.9	36
33	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. <i>Frontiers in Immunology</i> , 2019, 10, 853.	2.2	31
34	Post-transplant recurrence of atypical hemolytic uremic syndrome in a patient with thrombomodulin mutation. <i>Pediatric Transplantation</i> , 2013, 17, E177-81.	0.5	23
35	A Case of Familial Glomerulopathy With Fibronectin Deposits Caused by the Y973C Mutation in Fibronectin. <i>American Journal of Kidney Diseases</i> , 2013, 61, 514-518.	2.1	22
36	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. <i>Thrombosis and Haemostasis</i> , 2006, 96, 454-64.	1.8	20

#	ARTICLE	IF	CITATIONS
37	A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations. <i>Clinical and Experimental Nephrology</i> , 2011, 15, 269-274.	0.7	16
38	Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. <i>Pediatric Nephrology</i> , 2012, 27, 1995-1999.	0.9	15
39	Three novel mutations of the PKD1 gene in Italian families with autosomal dominant polycystic kidney disease. <i>Nephrology</i> , 1997, 10, 164-167.		14
40	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2002-2012.	2.2	12
41	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. <i>Journal of Biological Chemistry</i> , 2016, 291, 8214-8230a.	1.6	12
42	A new disease-causing mutation in the GAP-related domain of the NF1 gene. <i>Human Molecular Genetics</i> , 1993, 2, 1057-1059.	1.4	11
43	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. <i>Frontiers in Genetics</i> , 2021, 12, 670727.	1.1	11
44	Erroneous genetic risk assessment of Alport syndrome. <i>Lancet</i> , The, 1995, 346, 1237.	6.3	10
45	Rapid DNA-based prenatal diagnosis by genetic linkage in three families with Alport's syndrome. <i>American Journal of Kidney Diseases</i> , 1997, 30, 174-179.	2.1	9
46	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. <i>Frontiers in Medicine</i> , 2020, 7, 579418.	1.2	8
47	Congenital thrombotic thrombocytopenic purpura (cTTP) with two novel mutations. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1296-1298.	0.8	6
48	Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children. <i>Italian Journal of Pediatrics</i> , 2021, 47, 181.	1.0	6
49	A common polymorphism in exon 46 of the human autosomal dominant polycystic kidney disease 1 gene (PKD1). <i>Molecular and Cellular Probes</i> , 1996, 10, 463-465.	0.9	5
50	Detection of two different nonsense mutations in exon 44 of the PKD1 gene in two unrelated Italian families with severe autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 10-12.	0.4	5
51	Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations. <i>Pediatric Nephrology</i> , 2013, 28, 1141-1144.	0.9	3
52	Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 679048.	1.2	3
53	Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association. <i>Nephron</i> , 2019, 142, 264-270.	0.9	2
54	Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection. <i>CEN Case Reports</i> , 2013, 2, 34-37.	0.5	1

#	ARTICLE	IF	CITATIONS
55	IgA nephropathy and atypical hemolytic uremic syndrome: a case series and a literature review. Journal of Nephrology, 2021, , 1.	0.9	1
56	Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase.. Journal of Biological Chemistry, 2017, 292, 6094.	1.6	0
57	Unravelling the pathophysiology of C3G/IC-MPGN and how to predict disease progression and orient therapies. Molecular Immunology, 2017, 89, 178.	1.0	0
58	Interaction between multimeric VWF and complement: A fresh look to the pathophysiology of microvascular thrombosis. Molecular Immunology, 2017, 89, 133.	1.0	0